Skip to main content
Figure 3 | Arthritis Res Ther

Figure 3

From: Increased interleukin-17 production via a phosphoinositide 3-kinase/Akt and nuclear factor κB-dependent pathway in patients with rheumatoid arthritis

Figure 3

Effects of protein kinase inhibitors and anti-rheumatic drug on anti-CD3 triggered interleukin (IL)-17 production by peripheral blood mononuclear cells (PBMC) from patients with rheumatoid arthritis. PBMC pretreated for 1 hour with pyrrolidine dithiocarbamate (PDTC; 300 μM), curcumin (10 μM), LY294002 (20 μM), wortmannin (200 nM), Cyclosporin A (500 ng/ml), dexamethasone (DEX; 100 nM), FK506 (100 ng/ml), rapamycin (10 ng/ml), SB203580 (10 nM) or PD98059 (20 μM) in combination with anti-CD3 antibody (5 μg/ml). Culture supernatant was assayed for IL-17 as described in the Materials and methods section. Each value represents the mean and SEM of three independent experiments. *, P < 0.05; **, P < 0.005.

Back to article page